Search details
1.
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
Cell
; 164(3): 550-63, 2016 Jan 28.
Article
in English
| MEDLINE | ID: mdl-26824661
2.
PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis.
Cell
; 158(5): 1210, 2014 Aug 28.
Article
in English
| MEDLINE | ID: mdl-28917293
3.
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.
Genes Dev
; 27(13): 1462-72, 2013 Jul 01.
Article
in English
| MEDLINE | ID: mdl-23796897
4.
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
J Neurooncol
; 146(1): 79-89, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31776899
5.
Molecular Mechanisms of Treatment Resistance in Glioblastoma.
Int J Mol Sci
; 22(1)2020 Dec 31.
Article
in English
| MEDLINE | ID: mdl-33396284
6.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
N Engl J Med
; 372(26): 2481-98, 2015 Jun 25.
Article
in English
| MEDLINE | ID: mdl-26061751
7.
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
J Neurooncol
; 137(1): 39-47, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-29404979
8.
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
J Neurooncol
; 136(1): 79-86, 2018 Jan.
Article
in English
| MEDLINE | ID: mdl-28988377
9.
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Proc Natl Acad Sci U S A
; 112(11): 3421-6, 2015 Mar 17.
Article
in English
| MEDLINE | ID: mdl-25737557
10.
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
J Neurooncol
; 129(3): 487-494, 2016 09.
Article
in English
| MEDLINE | ID: mdl-27406589
11.
Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
Acta Neuropathol
; 130(4): 587-97, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26323991
12.
A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
Stem Cells
; 32(1): 301-12, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24038660
13.
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
J Neurooncol
; 119(1): 135-40, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-24803001
14.
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Cancer
; 119(15): 2747-53, 2013 Aug 01.
Article
in English
| MEDLINE | ID: mdl-23633392
15.
A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).
J Neurooncol
; 111(1): 33-9, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23086432
16.
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.
J Clin Oncol
; 41(32): 4945-4952, 2023 Nov 10.
Article
in English
| MEDLINE | ID: mdl-37935104
17.
Neuronal differentiation drives the antitumor activity of mitogen-activated protein kinase kinase (MEK) inhibition in glioblastoma.
Neurooncol Adv
; 5(1): vdad132, 2023.
Article
in English
| MEDLINE | ID: mdl-38130900
18.
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
Cancer
; 118(14): 3599-606, 2012 Jul 15.
Article
in English
| MEDLINE | ID: mdl-22086614
19.
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.
Nat Genet
; 54(12): 1881-1894, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36471067
20.
Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison.
J Neurooncol
; 104(1): 351-6, 2011 Aug.
Article
in English
| MEDLINE | ID: mdl-21221714